Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02110134 · ClinicalTrials.gov registry record · NA

A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma

A NA study of Melasma, sponsored by Cynosure.

Completed
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT02110134 is a NA study of Melasma that has completed, run by Cynosure. The registered enrollment target is 6 participants, below the 44-participant average among 8 other Melasma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02110134, a NA study of Melasma, has completed, sponsored by Cynosure.

COMPLETED
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare a hydroquinone skin care regimen alone to a combination of Revlite Laser treatment with a hydroquinone skin care regimen for the treatment of melasma.

Conditions Studied

Interventions

  • DEVICE Revlite Laser System with hydroquinone skin care regimen
  • OTHER Hydroquinone skin care regimen

Study Locations (1)

New York

  • NY Laser and Skin Care - New York

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2013-12
Est. Completion 2014-05
Phase NA

Sponsor

Cynosure

49 total trials

What the Registry Record Tells You About NCT02110134

The ClinicalTrials.gov registry entry for NCT02110134 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 44-participant average among 8 other Melasma trials with a reported enrollment target (86% lower). The listed sponsor is Cynosure, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melasma appearing as the primary indexed condition, and to 2 interventions - of which Revlite Laser System with hydroquinone skin care regimen is the first listed.

NCT02110134 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02110134 about?

NCT02110134 is a clinical study titled "A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma". The purpose of this study is to compare a hydroquinone skin care regimen alone to a combination of Revlite Laser treatment with a hydroquinone skin care regimen for the treatment of melasma.

What is the current status of trial NCT02110134?

This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2013-12. Estimated completion is 2014-05.

What conditions does trial NCT02110134 study?

This clinical trial studies the following conditions: Melasma.

What interventions are being tested in trial NCT02110134?

The interventions under investigation include: Revlite Laser System with hydroquinone skin care regimen (DEVICE), Hydroquinone skin care regimen (OTHER).

Who is sponsoring clinical trial NCT02110134?

This trial is sponsored by Cynosure, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02110134 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Melasma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.